Company: NKLR
Filing Date: 2025-12-16
Form Type: 424B3
Source: 0001213900-25-121900
Chunk: 43

Company: Terra Innovatum Global N.V.
Filing Date: 2025-12-16
Form: 424B3
Chunk 43
---
 to do among other things, one or more of the following: (i) cease selling, incorporating or using MMRs
that incorporate the challenged intellectual property; (ii) pay substantial damages; (iii) pay for and obtain a license from
the holder of the infringed intellectual property right, which may not be available on reasonable terms or at all; or (iv) redesign
part or all of our technology. In the event of a successful claim of infringement against us and our failure or inability to obtain a
license to the infringed technology, our business, prospects, operating results and financial condition could be materially adversely
affected. In addition, any litigation or claims, whether or not valid, could result in substantial costs and diversion of resources and
management’s focus and attention.

We also license patents
and other intellectual property from third parties, and we may face claims that the use of this intellectual property infringes the rights
of other third parties. In such cases, we may seek indemnification from the licensors under our license contracts with those licensors
or other damages. However, our rights to indemnification or damages may be unavailable or insufficient to cover our costs and losses,
depending on our use of the technology, whether we choose to retain control over conduct of the litigation, and other factors.

<div align='center'>17</div>

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our MMRs.

We cannot guarantee
that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration
of relevant patents, are complete or thorough because there may be hundreds of thousands of relevant patents worldwide. We also cannot
be certain that we have identified each and every third-party patent and pending application in the United States and abroad that
is relevant to or necessary for the commercialization of our MMRs in any jurisdiction. The scope of a patent claim is generally determined
by an interpretation of the law, the written disclosure in a patent, and the patent’s prosecution history. Our interpretation of
the relevance or the scope of a patent or a pending application may be incorrect or not accepted by a court of competent jurisdiction.
Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect
or inaccurate. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market
our